In this episode of Behind the Bell, CRISPR Therapeutics Chairman & CEO Samarth Kulkarni joined us at MarketSite to commemorate the historic first-ever approval of a CRISPR-based therapy and to celebrate innovation as CRISPR Therapeutics continues to expand and advance its pipeline of programs for rare and common diseases.
Watch more of Behind the Bell on Nasdaq.com: www.nasdaq.com/news-and-insig...
Негізгі бет Behind the Bell: CRISPR Therapeutics
Пікірлер